DUBLIN-3, a Phase (Ph) III Trial Comparing the Plinabulin (P)/Docetaxel(D) Combination with D Alone in Stage IIIb/IV NSCLC
Predictive Models for Tumor Cell Targeting with Plinabulin, Derived from In Vitro Screening and Affymetrix mRNA Expression Data
A Phase II Trial with the Combination of Plinabulin (Plin) Pegfilgrastim (Peg): Evaluation of the Reversal of Peg's Immune-Suppressive Potential by the Addition of Plinto Peg
Plinabulin, a Novel Small Molecule in Development for Chemotherapy-Induced-Neutropenia (CIN) Prevention, Mobilizes CD34+ Cells through a Mechanism of Action Different from G-CSF and from CXCR4 Inhibition
Pegfilgrastim, but not Plinabulin, Generates a Blood Myeloid Cell (BMC) Repertoire with a Predominant Immunosuppressive Phenotype
© 2020 BeyondSpring Inc. All rights reserved.